Pfizer Inc. $PFE Shares Acquired by AE Wealth Management LLC

Key Points

• AE Wealth Management LLC increased its stake in Pfizer by 17.4% in Q4, buying 216,102 shares to hold 1,454,562 shares worth $36,219,000.
• Pfizer beat Q4 estimates, reporting EPS of $0.66 versus $0.57 expected and revenue of $17.56 billion versus $16.93 billion, though revenue was down 1.2% year-over-year.
• Institutional ownership stands at 68.36%; analysts’ consensus is a Hold with an average price target of $28.45, and the stock has a market cap of $154.75 billion and a PE of 20.01.

AE Wealth Management LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 17.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,454,562 shares of the biopharmaceutical company's stock after buying an additional 216,102 shares during the period. AE Wealth Management LLC's holdings in Pfizer were worth $36,219,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. J.M. Arbour LLC purchased a new position in shares of Pfizer during the 4th quarter worth $219,000. Sightline Wealth Advisors LLC increased its stake in shares of Pfizer by 8.2% during the 4th quarter. Sightline Wealth Advisors LLC now owns 16,809 shares of the biopharmaceutical company's stock valued at $419,000 after acquiring an additional 1,277 shares during the last quarter. Lipe & Dalton raised its stake in Pfizer by 86.3% during the fourth quarter. Lipe & Dalton now owns 4,954 shares of the biopharmaceutical company's stock worth $123,000 after purchasing an additional 2,295 shares during the period. Argo Wealth Advisory LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $1,557,000. Finally, Inman Jager Wealth Management LLC increased its holdings in shares of Pfizer by 11.4% during the 4th quarter. Inman Jager Wealth Management LLC now owns 45,682 shares of the biopharmaceutical company's stock worth $1,137,000 after buying an additional 4,693 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Pfizer stock opened at $27.22 on Friday. The firm has a market capitalization of $154.75 billion, a PE ratio of 20.01 and a beta of 0.43. Pfizer Inc. has a one year low of $21.87 and a one year high of $28.75. The stock's 50 day moving average price is $27.27 and its 200 day moving average price is $26.02. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter last year, the company earned $0.63 earnings per share. Pfizer's revenue for the quarter was down 1.2% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PFE. Daiwa Securities Group cut Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. HSBC upped their price target on Pfizer from $29.00 to $32.00 and gave the stock a "buy" rating in a research note on Tuesday, March 17th. UBS Group lifted their price objective on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Monday. CICC Research began coverage on Pfizer in a report on Thursday. They set an "outperform" rating and a $33.00 target price for the company. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $28.45.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.